Crystalline free bases of C-Met inhibitor or crystalline acid salts thereof, and preparation methods and uses thereof

A crystalline acid salt of 9-((8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-yl)thio)-4-methyl-2H-[1,4]oxaazido[3,2-c]quinoline-3 (4H)-one, wherein the crystalline acid salt is an inorganic acid salt or an organic acid salt;

• wherein the inorganic acid salt is phosphate;
• and wherein the organic acid salt is selected from the group consisting of mesylate and 1,5-naphthalenedisulfonate;
• wherein:
• the phosphate salt is crystal form I of a phosphate salt, wherein crystal form I of the phosphate salt has an X-ray powder diffraction (XRPD) spectrum comprising peaks at diffraction angles (2θ) of 7.9±0.20, 12.8±0.2°, 15.9±0.2° and 18.3±0.2°;
• the mesylate salt is crystal form III of a mesylate salt, wherein crystal form III of the mesylate salt has an XRPD spectrum comprising peaks at diffraction angles (2θ) of 16.7±0.20, 19.3±0.2°, 23.2±0.2° and 26.5±0.2°;
• the 1,5-naphthalenedisulfonate salt is crystal form III of a 1,5-naphthalenedisulfonate salt wherein crystal form III of the the 1,5-naphthalenedisulfonate salt has an XRPD spectrum comprising peaks at diffraction angles (2θ) of 13.0±0.2°, 22.7±0.20, 24.1±0.20 and 25.7±0.20.